John Dyett – Startup Investor Profile

John Dyett, Co-Founder of Salem Partners, heads the firm’s efforts in the Life Sciences. Mr. Dyett has raised over $500 million of equity and completed multiple merger and acquisition assignments. Notable previous investments include Adams Respiratory Therapeutics and ZS Pharma. He played a key role in investments raising several rounds of venture capital. His partnership and collaboration styles involve active involvement in the investment committee. John Dyett’s track record includes successful IPOs and investment committee roles at Salem Partners. The specific geographical preference is not mentioned.

Location: Los Angeles, CA

Country: United States of America

Investment Regions:

Investment Stages: pre-seed, seed

Website:

AI Reasoning: Searches of Salem Partners team page and news, OncoNano and Coronado Aesthetics press, SEC filings and press coverage show historical investments (Adams Respiratory Therapeutics, ZS Pharma, Neos Therapeutics, Femasys, Allakos) with exits dated 2008 and earlier or around 2010s and a noted OncoNano Series A in 2018. No evidence of any investment activity by John Dyett within the last several years (no results in 2023-2025). The most recent verifiable company linked to him from sources is OncoNano (Series A coverage in 2018). Given inability to find any recent investments after 2018 or within the past 12 months, and absence of any 2024-2025 deal mentions, the default classification is used.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.